Tamoxifen is an antagonist of the Estrogen receptor in breast tissue via its active metabolite, 4-hydroxytamoxifen.
Tamoxifen is the usual endocrine (anti-estrogen) therapy for ER+ Breast cancer in pre-menopausal women, and is also a standard in post-menopausal women although aromatase inhibitors are also frequently used in that setting.
Table of Contents
Incoming Links #
Related Medical Conditions (MedicalCondition 0) #
Related Articles (Article 1) #
Related Codes (Code 2) #
Related Books (Book 3) #
Related Medical Scholarly Articles (MedicalScholarlyArticle 4) #
Suggested Pages #
- 0.139 HMEC
- 0.091 CDH1
- 0.089 Trastuzumab
- 0.043 MYC
- 0.042 Drug discovery
- 0.042 Bevacizumab
- 0.035 Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer
- 0.030 Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response
- 0.026 Identification of Biomarkers for Breast Cancer Using Databases
- 0.026 KOHBRA
- More suggestions...